Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ValiRx plc ( (GB:VAL) ) just unveiled an announcement.
ValiRx plc has announced a change in its shareholder voting rights, with Peel Hunt LLP acquiring or disposing of a significant portion of the company’s shares. As of January 10, 2025, Peel Hunt LLP holds 10.32% of the voting rights, indicating a notable shift from a previous position of 9.61%. This change in voting rights could impact the company’s governance and strategic decision-making, reflecting potential shifts in stakeholder influence and investment dynamics.
More about ValiRx plc
ValiRx plc operates within the biotechnology sector, primarily focusing on developing and commercializing novel treatments for cancer and other diseases. The company is positioned in the UK and engages in the research and development of innovative therapeutics aimed at addressing critical unmet medical needs.
YTD Price Performance: -12.90%
Average Trading Volume: 7,486,322
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.53M
Learn more about VAL stock on TipRanks’ Stock Analysis page.
